Drawing for MERXIN

USPTO serial 79229680

MERXIN

Reviewed by CopyMark Law Group

Reg. 5730393Status 739Registered
Filing date
Status date
Registration date
Apr 23, 2019
Examiner
COLLOPY, DIANE PATRICIA
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with MERXIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Geza C Ziegler Jr

Geza C Ziegler Jr ZIEGLER IP LAW GROUP LLC.2000 Post Road, Suite 205Fairfield, CT 06824United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ]SECTION 7(e) - CANCELLED—
009[ Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment ] * Laboratory equipment for scientific purposes, namely, vials *SECTION 7(e) - CANCELLED—
010* medical inhalers that are sold empty and in bulk via business-to-business transactions through business-to-business channels of trade * [ [ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical syringes sold empty for administering pharmaceuticals; Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; ] Medical inhalers * Sold Empty * [ ; Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseases ] ]ACTIVE—
042* design and development of medical inhalers sold empty and in bulk to third-party drug manufacturers and not for sale directly to end users * [ Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to [ design engineering ] * design of new products for others * ; Advisory services relating to [ product testing ] * testing of new products for others * ; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; [ engineering design and consultancy ] * new product design and consultancy services * ; Professional consultancy relating to medical technology; [ engineering project management services, not for business purposes; Engineering research ] * project management services in the field of medical and pharmaceutical engineering, not for business purposes; Scientific research in the field of medical and pharmaceutical engineering * ; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines ]ACTIVE—
044[ Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ]SECTION 7(e) - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 17, 2025NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Jul 17, 2025C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jul 15, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 22, 2025ES75TEAS SECTION 71 & 15 RECEIVED—
Apr 17, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 17, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Apr 17, 2025EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Apr 17, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 17, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 16, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 2, 2024INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Apr 23, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 23, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Aug 24, 2023NCP7NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED—
Aug 23, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 23, 2023C7P.CANCELLED SEC. 7 - PARTIAL—
Aug 22, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 15, 2023ES7RTEAS SECTION 7 REQUEST RECEIVED—
Apr 11, 2023NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Mar 7, 2023A7OKAMENDMENT UNDER SECTION 7 - PROCESSED—
Mar 6, 2023PLGLASSIGNED TO PARALEGAL—
Feb 15, 2023ES7RTEAS SECTION 7 REQUEST RECEIVED—
Aug 23, 2022INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Jul 9, 2022INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 5, 2022A7OKAMENDMENT UNDER SECTION 7 - PROCESSED—
Jan 4, 2022EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Jan 3, 2022PRAMPOST REGISTRATION ACTION MAILED - SEC. 7—
Jan 3, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 24, 2021WDRLOTQR WITHDRAWAL FROM PUBLICATION—
Oct 27, 2021NCP7NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED—
Oct 26, 2021XXXXPOST REGISTRATION ACTION CORRECTION—
Oct 26, 2021C7P.CANCELLED SEC. 7 - PARTIAL—
Oct 22, 2021EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Oct 18, 2021PRAMPOST REGISTRATION ACTION MAILED - SEC. 7—
Oct 14, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 18, 2021ES7RTEAS SECTION 7 REQUEST RECEIVED—
May 18, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 18, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 18, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 18, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 18, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 18, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 18, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 18, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 18, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 18, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
May 18, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 18, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 18, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 30, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 14, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 14, 2019FIMPFINAL DISPOSITION PROCESSED—
Jul 23, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 14, 2019ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Apr 23, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 5, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 5, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 2, 2019GPNXNOTIFICATION PROCESSED BY IB—
Jan 16, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 16, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 16, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 28, 2018ALIEASSIGNED TO LIE—
Dec 10, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 10, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Dec 10, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 10, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 10, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 27, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 26, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 26, 2018ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 24, 2018GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 24, 2018GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 24, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 29, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 29, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 29, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 23, 2018RFNTREFUSAL PROCESSED BY IB—
Jun 1, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 1, 2018RFRRREFUSAL PROCESSED BY MPU—
May 24, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 23, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 3, 2018RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Apr 29, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 28, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 27, 2018DOCKASSIGNED TO EXAMINER—
Apr 10, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 6, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 5, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance